These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27719738)

  • 1. Bendamustine-induced nephrogenic diabetes insipidus
.
    Derman BA; Jain M; McAninch EA; Gashti C
    Clin Nephrol; 2017 Jan; 87 (2017)(1):47-50. PubMed ID: 27719738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.
    Uwumugambi NA; Sanchorawala V; Shelton AC; Stern L; Gordon CE
    Am J Kidney Dis; 2017 Feb; 69(2):317-319. PubMed ID: 27780577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine-induced nephrogenic diabetes insipidus - A case report.
    Desjardins A; Le-Nguyen V; Turgeon-Mallette L; Vo C; Boudreault JS; Rioux JP; Feng X; Veilleux A
    J Oncol Pharm Pract; 2022 Jan; 28(1):205-210. PubMed ID: 33990157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
    Shikdar S; Totton D; Turco T; Rachshtut M
    Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
    Mulay S; Boruchov A
    Leuk Lymphoma; 2015 Mar; 56(3):805-7. PubMed ID: 24913498
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
    Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
    Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
    [No Abstract]   [Full Text] [Related]  

  • 7. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
    Laurenti L; Autore F; Innocenti I; D'Arena G; Coscia M; Mondello P; Chiusolo P; Bellesi S; Efremov DG; Sica S; Mauro FR
    Leuk Lymphoma; 2016 Oct; 57(10):2429-31. PubMed ID: 26818825
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus.
    Hoang S; Pujar T; Bellorin-Font E; Edwards JC; Miyata KN
    CEN Case Rep; 2024 Jun; 13(3):194-198. PubMed ID: 37897631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.
    Fallon MJ; Heck JN
    J Oncol Pharm Pract; 2015 Oct; 21(5):388-92. PubMed ID: 25005569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukaemia cutis after starting bendamustine: cause or coincidence?
    Mawri S; Nabi S; Jallad B; Won J
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26392439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Rare Case of Coexisting Psychogenic Polydipsia and Nephrogenic Diabetes Insipidus With Lithium Therapy.
    Antala D; Sharma A; Adhikari A; Luitel P; Hirsch S
    Cureus; 2022 Mar; 14(3):e23438. PubMed ID: 35481319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
    Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
    Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide-induced nephrogenic diabetes insipidus responsive to supraphysiologic doses of intravenous desmopressin.
    Sohail MA; Hassanein M; Rincon-Choles H
    Clin Nephrol Case Stud; 2021; 9():87-92. PubMed ID: 34235046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial nephrogenic diabetes insipidus associated with Castleman's disease.
    Kim M; Choi HS; Bae EH; Ma SK; Kim SW; Kim CS
    BMC Nephrol; 2019 May; 20(1):168. PubMed ID: 31088379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
    Ames PR; Merashli M; Gentile F
    Eur J Immunol; 2019 Jun; 49(6):969-970. PubMed ID: 30893471
    [No Abstract]   [Full Text] [Related]  

  • 19. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
    Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.